Pharmacokinetics (PK) and PK modeling of the first-in-class HBV core inhibitor NVR 3-778 dosed once-(QD) or twice daily (BD) in healthy volunteers (HVs) and HBeAg-positive patients with chronic HBV infection (CHBV)
Hepatology